The conference brings to Turin a wide-ranging discussion of the transformations redefining contemporary cardiology. Clinical research, technological innovation, and new care models intertwine in a journey that highlights the main emerging challenges and the opportunities offered by advanced therapies, advanced diagnostics, and increasingly personalized approaches, with a careful eye on their real-world impact on daily practice.

Turin hosted "Change in Cardiology 2025," a key scientific and educational event for Italian cardiology. Innovation, research, and multidisciplinary discussion fueled the conference, focusing on new therapies, emerging technologies, and evolving clinical scenarios. In this series of video interviews produced by YouMed, conference participants share their thoughts, experiences, and visions for the future of cardiology.

Convegno. La malattia cardiaca affrontata con approccio olistico, ponendo al centro la persona e non le singole specialità

Focus sulle modalità di contrasto allo sviluppo di una delle patologie cardiovascolari più insidiose

Corso teorico pratico d’impianto multidisciplinare sulle innovazioni tecnologiche nel settore cardiovascolare

Un nuovo programma educazionale finalizzato allo sviluppo di farmaci per lo scompenso cardiaco

Un numero crescente di cittadini dell'area lombarda è oggi in grado di gestire un arresto cardiaco e di utilizzare correttamente un defibrillatore: è solo uno dei risultati del lavoro portato avanti dalla Centrale 118 milanese.

Alla Stazione Leopolda di Firenze i soci GISE hanno dato vita ad un evento di studio, aperto alle istituzioni sanitarie e ai principali attori del settore cardiovascolare.

At the 77th SIC national congress, a symposium was held, sponsored by Daiichi-Sankyo, on the characteristics of Edoxaban, the latest addition to the family of NAOs (New Oral Anticoagulants). Strengthened by the results of the Engage AF-TIMI 48 study, which involved over 21 thousand patients, segmented into different subgroups with specific needs, Edoxaban is proposed as an anticoagulant capable of personalising the dosage in non-valvular atrial fibrillation, attesting to high levels of efficacy and safety. Similar results are expected in the treatment of venous thromboembolism, based on the evidence that emerged following extensive in-depth analyses of the Hokusai study.